Percutaneous Drainage of Hydatid Cyst in the Liver as a Primary Treatment: Review of 52 Consecutive Cases with Long-term Follow-up

2000 ◽  
Vol 55 (11) ◽  
pp. 839-848 ◽  
Author(s):  
ZELJKO B BOSANAC ◽  
LJUBOMIR LISANIN
Keyword(s):  
Hydatid Cyst ◽  
Percutaneous Drainage ◽  
Primary Treatment ◽  
Treatment Review ◽  
Long Term Follow Up

scholarly journals Diagnosis, treatment, and long-term follow up of a patient with a hydatid cyst of the left ventricle.

Heart ◽  
1994 ◽  
Vol 72 (6) ◽  
pp. 592-592 ◽  
Author(s):  
A G Kontopoulos ◽  
M J Avramides ◽  
V G Athyros
Keyword(s):  
Left Ventricle ◽  
Hydatid Cyst ◽  
Long Term Follow Up

scholarly journals Long Term Follow-up Results of External Beam Radiotherapy as Primary Treatment for Retinoblastoma

2010 ◽  
Vol 25 (4) ◽  
pp. 546 ◽  
Author(s):  
Sang Yul Choi ◽  
Mi-Sook Kim ◽  
SungYul Yoo ◽  
ChulKoo Cho ◽  
YoungHoon Ji ◽  
...  
Keyword(s):  
External Beam Radiotherapy ◽  
Primary Treatment ◽  
External Beam ◽  
Long Term Follow Up

A New Percutaneous Approach for the Treatment of Hydatid Cyst of the Kidney: Long-term Follow-up

2005 ◽  
Vol 37 (3) ◽  
pp. 461-464 ◽  
Author(s):  
Necati Örmeci ◽  
Ramazan Idilman ◽  
Ali Tüzün ◽  
Hakan Erdem ◽  
Murat Palabıyıkoğlu
Keyword(s):  
Hydatid Cyst ◽  
Percutaneous Approach ◽  
Long Term Follow Up

scholarly journals A pure non-gestational ovarian choriocarcinoma with delayed solitary brain metastases: Case report and review of the literature

2015 ◽  
Vol 06 (04) ◽  
pp. 578-581 ◽  
Author(s):  
K.V.L Narasinga Rao ◽  
Subhas Konar ◽  
Jagathlal Gangadharan ◽  
V. Vikas ◽  
S. Sampath
Keyword(s):  
Brain Metastases ◽  
Single Agent ◽  
Germ Cell Tumors ◽  
Malignant Tumour ◽  
Primary Treatment ◽  
Gestational Choriocarcinoma ◽  
Long Term Follow Up ◽  
Solitary Brain Metastases

ABSTRACTChoriocarcinoma is the most malignant tumour of gestational trophoblastic origin. Most ovarian choriocarcinomas are gestational in origin and usually metastasize to the ovary from uterine or tubal choriocarcinoma. Non gestational choriocarcinoma (NGOC) of the ovary is exceedingly rare and usually seen along with other germ cell tumors. Non gestational choriocarcinoma has been found to be resistant to single-agent chemotherapy and has a worse prognosis than gestational choriocarcinoma. We are reporting long term follow up of published rare case of pure non gestational ovarian choriocarcinoma (NGOC) with concurrent metastases to the spleen and adrenal glands, who developed a delayed solitary brain metastases, two years after completion of primary treatment. Surgery along with triple agent chemotherapy and radiotherapy was found to give good remission in this aggressive disease.

scholarly journals Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

2020 ◽  
Vol 4 (16) ◽  
pp. 3952-3959
Author(s):  
Jorge J. Castillo ◽  
Kirsten Meid ◽  
Catherine A. Flynn ◽  
Jiaji Chen ◽  
Maria G. Demos ◽  
...  
Keyword(s):  
Median Time ◽  
Progression Free Survival ◽  
Primary Treatment ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia ◽  
Mutational Status ◽  
Long Term Follow Up ◽  
Treatment Naïve

Abstract Proteasome inhibition is a standard of care for the primary treatment of patients with Waldenström macroglobulinemia (WM). We present the long-term follow-up of a prospective, phase II clinical trial that evaluated the combination of ixazomib, dexamethasone, and rituximab (IDR) in 26 treatment-naive patients with WM. IDR was administered as 6 monthly induction cycles followed by 6 every-2-month maintenance cycles. The MYD88 L265P mutation was detected in all patients, and CXCR4 mutations were detected in 15 patients (58%). The median time to response (TTR) and time to major response (TTMR) were 2 and 6 months, respectively. Patients with and without CXCR4 mutations had median TTR of 3 months and 1 month, respectively (P = .003), and median TTMR of 10 months and 3 months, respectively (P = .31). The overall, major, and very good partial response (VGPR) rates were 96%, 77%, and 19%, respectively. The rate of VGPR in patients with and without CXCR4 mutations were 7% and 36%, respectively (P = .06). The median progression-free survival (PFS) was 40 months, the median duration of response (DOR) was 38 months, and the median time to next treatment (TTNT) was 40 months. PFS, DOR, and TTNT were not affected by CXCR4 mutational status. The safety profile was excellent with no grade 4 adverse events or deaths to date. IDR provides a safe and effective frontline treatment option for symptomatic patients with WM. This study was registered at www.clinicaltrials.gov as #NCT02400437.

scholarly journals Splenomegaly in sarcoidosis: Frequency, treatment, prognosis and long-term follow-up

2015 ◽  
Vol 143 (5-6) ◽  
pp. 279-283 ◽  
Author(s):  
Zora Pavlovic-Popovic ◽  
Bojan Zaric ◽  
Zdravko Kosjerina ◽  
Dragana Petrovic
Keyword(s):  
Clinical Characteristics ◽  
Primary Treatment ◽  
Prospective Analysis ◽  
Real Frequency ◽  
Long Term Follow Up ◽  
Splenic Involvement ◽  
History Of ◽  
Treatment Prognosis

Introduction. The splenic involvement is common in sarcoidosis, but its real frequency is still obscure, depending doubtless on the method of splenomegaly detection. Splenomegaly may be accompanied with pain or anemia, leucopenia and thrombocytopenia. Objective. The aim of this study was to investigate the frequency of splenomegaly related to clinical characteristics of sarcoidosis and to solve the dilemma - whether to introduce medicaments, and when to perform splenectomy. Methods. The method of the study is a retrospective and prospective analysis of the patients? material. Results. The study included 540 patients with sarcoidosis in a 20-year period. Of them, 26% had splenomegaly detected by computerized tomography screening. Splenomegaly was more frequently registered in the patients with a longer history of sarcoidosis (38%), as compared to those with a shorter history of the disease (23%) (p<0.05). Splenomegaly was more frequently registered in the patients with other extrapulmonary lesions detected (33%) than in those who had no extrapulmonary manifestations of sarcoidosis (17%) (p<0.01). Indications, possible benefits and complications of splenectomy were analysed in 11 sarcoidosis patients undergoing this intervention for various reasons, of which the follow-up period ranged from one to 20 years. Conclusion. Splenomegaly was more frequent in chronic cases or in the patients with established sarcoid lesions of other extrapulmonary organs. The primary treatment of uncomplicated symptomatic splenic sarcoidosis includes medicamentous therapy. Occasionally, splenectomy is required. Prognostically, splenomegaly indicates an unfavorable course of the disease.

Gamma surgery in the treatment of nonsecretory pituitary macroadenoma

2006 ◽  
Vol 104 (6) ◽  
pp. 876-883 ◽  
Author(s):  
Vincenzo Mingione ◽  
Chun Po Yen ◽  
Mary Lee Vance ◽  
Melita Steiner ◽  
Jason Sheehan ◽  
...  
Keyword(s):  
Hormone Replacement ◽  
Primary Treatment ◽  
Pituitary Macroadenoma ◽  
University Of Virginia ◽  
Peripheral Dose ◽  
Fractionated Radiotherapy ◽  
Long Term Follow Up ◽  
Fully Functioning

Object The authors report on a retrospective analysis of the imaging and clinical outcomes following gamma surgery in 100 patients with nonsecretory pituitary macroadenoma. Methods Between June 1989 and March 2004, 100 consecutive patients with nonsecretory pituitary macroadenoma were treated at the Lars Leksell Center for Gamma Surgery, University of Virginia Health System (Charlottesville, VA). Ninety-two patients had residual or recurrent macroadenoma following one or more surgical procedures. In eight patients, gamma surgery was the primary treatment. Ten patients received conventional fractionated radiotherapy before the gamma surgery. Sixty-nine patients required hormone replacement therapy for one or more deficits before gamma knife treatment. Peripheral doses between 5 and 25 Gy (mean 18.5 Gy) were administered. Imaging and endocrinological follow-up evaluations were performed in 90 patients; these studies ranged from 6 to 142 months (mean 44.9 months) and 6 to 127 months (mean 47.9 months), respectively. Tumor volume decreased in 59 patients (65.6%), remained unchanged in 24 (26.7%), and increased in seven (7.8%). The minimal effective peripheral dose was 12 Gy; peripheral doses greater than 20 Gy did not seem to provide additional benefit. Of 61 patients with a partially or fully functioning pituitary gland and follow-up data, 12 (19.7%) suffered new hormone deficits following gamma surgery. In patients with endocrinological follow-up data that had been collected over more than 2 years, the rate of new deficits was 25%. No neurological morbidity or death was related to treatment. Conclusions Current experience suggests that gamma surgery is an appropriate means of managing recurrent or residual nonsecretory pituitary macroadenoma following microsurgery and a primary treatment in selected patients. To evaluate definite rates of recurrence and new endocrine deficiencies, long-term follow-up studies are needed.

Limits of 18F-Fluorodeoxyglucose Positron Emission Tomography in Recurrence Diagnosis of Borderline Ovarian Tumor

2010 ◽  
Vol 20 (5) ◽  
pp. 694-697
Author(s):  
Margherita Giorgini ◽  
Claudia Marchetti ◽  
Violante Di Donato ◽  
Jacopo Tesei ◽  
Natalina Manci ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Primary Treatment ◽  
Emission Tomography ◽  
Borderline Ovarian Tumor ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Positron Emission ◽  
Long Term Follow Up ◽  
Fluorodeoxyglucose Positron Emission

Most borderline ovarian tumors (BOT) occur in young women and exhibit a low malignant behavior. Nevertheless, an accurate long-term follow-up is required because, frequently, recurrence arises after many years from primary treatment, especially in patients affected by BOT with invasive peritoneal implants, which have a worse prognosis. We report the case of a pelvic recurrence of serous BOT firstly suspected by physical examination but misdiagnosed by 18F-fluorodeoxyglucose positron emission tomography and computed tomography and identified only by magnetic resonance imaging, 7 years after primary treatment. We also reviewed the literature concerning the role of 18F-fluorodeoxyglucose positron emission tomography in the management and follow-up of BOT.

The Outcome of Treatment of Flexor Sheath (seed) Ganglia by a Percutaneous Partial Pulley Release

2017 ◽  
Vol 22 (02) ◽  
pp. 219-221
Author(s):  
David Lavalette ◽  
Grey Giddins
Keyword(s):  
Complete Resolution ◽  
Retrospective Cohort ◽  
Surgical Excision ◽  
Primary Treatment ◽  
Percutaneous Release ◽  
Long Term Follow Up ◽  
Local Tenderness ◽  
The Mean

Background: The aims of this study were to assess the safety and efficacy of a technique of partial percutaneous pulley release. Methods: A retrospective cohort study was undertaken treating adults with seed ganglia with a percutaneous pulley release. The patients were reviewed independently after a mean of 6 (range 6–36) months. Results: We treated 24 patients over a 3 year period. There were 14 women and ten men. The mean age was 39 (range 17-65) years. We were able to assess 21 patients with long term follow up. There was complete resolution in 14 (2/3) and partial resolution in four. The remaining three patients had persisting symptoms and requested open surgical excision. Apart from local tenderness and failure of resolution there were no complications of percutaneous pulley release. Conclusions: Bursting or aspiration of flexor sheath ganglia appears to be the best primary treatment. If the ganglion recurs, this study suggests a percutaneous release is safe and will resolve the symptoms in most patients.

Sign in / Sign up

Export Citation Format

Share Document